Spots Global Cancer Trial Database for t cell
Every month we try and update this database with for t cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| T Helper Cytokines in End Stage Colorectal Cancers | NCT04540146 | Colorectal Canc... | Flow-Cytometric... | 18 Years - 80 Years | Istanbul Training and Research Hospital | |
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | NCT06197672 | Acute Myeloid L... | CD4CAR | 18 Years - | Indiana University | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | NCT01044069 | Leukemia Acute Lymphobla... | gene-modified T... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma | NCT01238159 | Extranodal NK-T... | CCRT+MIDLE chem... | 18 Years - | Samsung Medical Center | |
| Assessing the Immunogenicity of pING-hHER3FL | NCT03832855 | Advanced Cancer | pING-hHER3FL | 18 Years - | Duke University | |
| Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | NCT03680560 | Solid Tumor HER-2 Protein O... | ACTR T Cell Pro... Trastuzumab | 18 Years - 75 Years | Cogent Biosciences, Inc. | |
| Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer | NCT01783951 | Gastric Cancer | DC-CIK S-1 Cisplatin | 18 Years - 80 Years | Capital Medical University | |
| COVID-19-Study of Immune Responses Following Vaccination Against SARS-CoV-2 | NCT04836793 | Cancer Elderly Healthy Aging | Additional biol... | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | NCT05686226 | Cervical Cancer Throat Cancer Oropharynx Canc... Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer Metastatic Canc... HPV-Related Mal... HPV-Related Car... HPV-Related Cer... HPV-Related Squ... HPV-Related Ade... HPV Positive Or... HPV-Associated ... HPV-Related Ade... HPV-Related End... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... HPV Positive Re... | E7 TCR-T cells | 18 Years - | Rutgers, The State University of New Jersey | |
| CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | NCT06358053 | Cervical Cancer Anal Cancer Head and Neck C... Other Solid Tum... | CRTE7A2-01 TCR-... | 18 Years - 65 Years | Corregene Biotechnology Co., Ltd | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells | NCT03535246 | Cancer | Engineered Immu... | 1 Year - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT01186328 | Lymphoblastic L... Lymphoblastic L... Leukemia, Lymph... Leukemia, Lymph... | EZN-3042 Cytarabine Doxorubicin Prednisone Vincristine PEG-asparaginas... Methotrexate Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer | NCT05354375 | Immunotherapy | CAR-T cell immu... | 18 Years - 75 Years | The Affiliated Hospital of Xuzhou Medical University | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL | NCT01703364 | CLL Chronic Lymphoc... | Lenalidomide | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors | NCT05902520 | HNSCC Melanoma Gynecologic Can... Colorectal Canc... Lung Cancer Urogenital Canc... | DP CD8 TIL DP CD8 TIL KD Low dose IL-2 | 18 Years - | AgonOx, Inc. | |
| Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma | NCT04969354 | Immunotherapy | CAR-T cell immu... | 18 Years - 70 Years | The Affiliated Hospital of Xuzhou Medical University | |
| A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | NCT03632941 | Breast Cancer HER2+ Breast Ca... | VRP-HER2 Pembrolizumab | 18 Years - | Duke University | |
| Assessing the Immunogenicity of pING-hHER3FL | NCT03832855 | Advanced Cancer | pING-hHER3FL | 18 Years - | Duke University | |
| Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | NCT00981799 | Relapsed T-Cell... Relapsed T-Cell... | Nelarabine Etoposide Cyclophosphamid... Methotrexate Filgrastim | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer | NCT05354375 | Immunotherapy | CAR-T cell immu... | 18 Years - 75 Years | The Affiliated Hospital of Xuzhou Medical University | |
| T Helper Cytokines in End Stage Colorectal Cancers | NCT04540146 | Colorectal Canc... | Flow-Cytometric... | 18 Years - 80 Years | Istanbul Training and Research Hospital | |
| NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | NCT02542124 | Cutaneous T Cel... Mycosis Fungoid... Sézary Syndrome | NM-IL-12 and TS... | 18 Years - | Neumedicines Inc. | |
| Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors | NCT05902520 | HNSCC Melanoma Gynecologic Can... Colorectal Canc... Lung Cancer Urogenital Canc... | DP CD8 TIL DP CD8 TIL KD Low dose IL-2 | 18 Years - | AgonOx, Inc. | |
| Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia | NCT03186118 | CD 19+ Acute Le... | T-cell Antigen ... | 1 Year - 30 Years | Seattle Children's Hospital | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma | NCT01948180 | Lymphoma, Extra... EBV | baltaleucel-T | 18 Years - | Cell Medica Ltd | |
| QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02099539 | Relapsed or Ref... | ALT-803 | 18 Years - | Altor BioScience | |
| Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma | NCT02336165 | Glioblastoma | Durvalumab Standard radiot... Bevacizumab | 18 Years - | Ludwig Institute for Cancer Research | |
| Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma | NCT04969354 | Immunotherapy | CAR-T cell immu... | 18 Years - 70 Years | The Affiliated Hospital of Xuzhou Medical University | |
| Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas | NCT02763254 | Hodgkin Lymphom... Lymphoma, Large... Post-transplant... | baltaleucel-T | 12 Years - | Cell Medica Ltd | |
| Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | NCT03266692 | Multiple Myelom... Multiple Myelom... Refractory Mult... | ACTR087 SEA-BCMA | 18 Years - 80 Years | Cogent Biosciences, Inc. | |
| Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | NCT03189836 | Lymphoma | ACTR707 rituximab | 18 Years - 80 Years | Cogent Biosciences, Inc. | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | NCT06197672 | Acute Myeloid L... | CD4CAR | 18 Years - | Indiana University | |
| Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | NCT00981799 | Relapsed T-Cell... Relapsed T-Cell... | Nelarabine Etoposide Cyclophosphamid... Methotrexate Filgrastim | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | NCT03189836 | Lymphoma | ACTR707 rituximab | 18 Years - 80 Years | Cogent Biosciences, Inc. | |
| Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies | NCT05237206 | Oncology | SUPLEXA | 18 Years - | Alloplex Biotherapeutics Inc | |
| Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells | NCT03535246 | Cancer | Engineered Immu... | 1 Year - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT01186328 | Lymphoblastic L... Lymphoblastic L... Leukemia, Lymph... Leukemia, Lymph... | EZN-3042 Cytarabine Doxorubicin Prednisone Vincristine PEG-asparaginas... Methotrexate Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma | NCT01948180 | Lymphoma, Extra... EBV | baltaleucel-T | 18 Years - | Cell Medica Ltd | |
| A Study of the Safety and Efficacy of EBV Specific T-cell Lines | NCT02580539 | Epstein-Barr Vi... Post-Transplant... Lymphoma | Group A Group B | 18 Years - | Maisonneuve-Rosemont Hospital | |
| QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02099539 | Relapsed or Ref... | ALT-803 | 18 Years - | Altor BioScience | |
| A Study of the Safety and Efficacy of EBV Specific T-cell Lines | NCT02580539 | Epstein-Barr Vi... Post-Transplant... Lymphoma | Group A Group B | 18 Years - | Maisonneuve-Rosemont Hospital | |
| CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) | NCT06345027 | Leukemia, Myelo... Leukemia, B-cel... Leukemia, T-Cel... Lymphoma | Treatment Arm A | - 75 Years | Baylor College of Medicine | |
| QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02099539 | Relapsed or Ref... | ALT-803 | 18 Years - | Altor BioScience |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
